• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

严重α1-抗胰蛋白酶缺乏症(PiZZ型)患者的肺功能、吸烟与生存情况

Lung function, smoking and survival in severe alpha 1-antitrypsin deficiency, PiZZ.

作者信息

Wu M C, Eriksson S

机构信息

National Heart, Lung and Blood Institute, Bethesda, MD 20892.

出版信息

J Clin Epidemiol. 1988;41(12):1157-65. doi: 10.1016/0895-4356(88)90019-4.

DOI:10.1016/0895-4356(88)90019-4
PMID:3264848
Abstract

Lung function, smoking, age and mortality data in 158 adult severe alpha 1-antitrypsin deficient, PiZZ individuals, followed from 1963 to 1982 were analyzed. Low initial FEV1 value was significantly associated with increased mortality (p less than 0.005). A 3 yr mortality rate of 40% was found in individuals whose initial FEV1 values were less than 30% of that predicted. In contrast, the corresponding 3-yr mortality among those whose initial FEV1 values were between 30 and 65% of that predicted was only 7%. Smokers were found to have significantly lower FEV1 levels (p = 0.008) and higher mortality (p less than 0.005) than non-smokers. The difference between current and ex-smokers in mortality and FEV1 level were not statistically significant (p = 0.9 and p greater than 0.25, respectively). Cross-sectional analysis of the initial FEV1 values indicated a significant decline (p less than 0.005) of FEV1 with increasing age. This decline was greater among smokers than non-smokers. Longitudinal analysis of FEV1 rates of decline in 80 cases with follow-up FEV1 measurements failed to detect any significant differences between smokers and non-smokers, but was performed late in the disease process. The application of these results to the planning of studies on replacement therapy, smoking intervention strategy and longitudinal follow-up is discussed.

摘要

对1963年至1982年随访的158例成年重度α1抗胰蛋白酶缺乏症(PiZZ型)患者的肺功能、吸烟情况、年龄和死亡率数据进行了分析。初始第一秒用力呼气容积(FEV1)值较低与死亡率增加显著相关(p<0.005)。初始FEV1值低于预测值30%的患者3年死亡率为40%。相比之下,初始FEV1值在预测值的30%至65%之间的患者相应的3年死亡率仅为7%。发现吸烟者的FEV1水平显著低于非吸烟者(p = 0.008),死亡率高于非吸烟者(p<0.005)。当前吸烟者与既往吸烟者在死亡率和FEV-1水平上的差异无统计学意义(分别为p = 0.9和p>0.25)。对初始FEV1值的横断面分析表明,FEV1随年龄增长显著下降(p<0.005)。吸烟者的这种下降幅度大于非吸烟者。对80例有随访FEV1测量值的患者进行FEV1下降率的纵向分析,未发现吸烟者与非吸烟者之间有任何显著差异,但该分析是在疾病过程后期进行的。讨论了将这些结果应用于替代疗法研究规划(替代疗法研究规划)、吸烟干预策略和纵向随访的情况。 (注:最后一句中“替代疗法研究规划”原文表述似乎有误,推测可能是“替代疗法研究计划”之类,但按要求未做修改)

相似文献

1
Lung function, smoking and survival in severe alpha 1-antitrypsin deficiency, PiZZ.严重α1-抗胰蛋白酶缺乏症(PiZZ型)患者的肺功能、吸烟与生存情况
J Clin Epidemiol. 1988;41(12):1157-65. doi: 10.1016/0895-4356(88)90019-4.
2
Aspects of treatment in alpha 1-antitrypsin deficiency: insights derived from a Swedish PiZZ series.α1-抗胰蛋白酶缺乏症的治疗方面:来自瑞典PiZZ队列的见解
Eur Respir J Suppl. 1990 Mar;9:39s-43s.
3
Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 years.通过新生儿筛查确定的瑞典α1-抗胰蛋白酶缺乏队列在37至40岁时的健康状况和肺功能。
Int J Chron Obstruct Pulmon Dis. 2017 Feb 2;12:495-500. doi: 10.2147/COPD.S120241. eCollection 2017.
4
Decline in FEV and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency.严重的α-1 抗胰蛋白酶缺乏症个体的 FEV 下降和住院加重。
Int J Chron Obstruct Pulmon Dis. 2019 May 23;14:1075-1083. doi: 10.2147/COPD.S195847. eCollection 2019.
5
Decline in FEV1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ).重度α1-抗胰蛋白酶缺乏症(PiZZ型)患者中,第一秒用力呼气容积(FEV1)下降与吸烟状况的关系。
Eur Respir J. 1999 Feb;13(2):247-51. doi: 10.1183/09031936.99.13224799.
6
Intensive smoking diminishes the differences in quality of life and exacerbation frequency between the alpha-1-antitrypsin deficiency genotypes PiZZ and PiSZ.重度吸烟会缩小α-1-抗胰蛋白酶缺乏症基因型 PiZZ 和 PiSZ 之间生活质量和恶化频率的差异。
Respir Med. 2017 Sep;130:1-8. doi: 10.1016/j.rmed.2017.07.004. Epub 2017 Jul 8.
7
Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group.α1-抗胰蛋白酶严重缺乏个体的生存率及第一秒用力呼气量下降情况。α1-抗胰蛋白酶缺乏症注册研究组
Am J Respir Crit Care Med. 1998 Jul;158(1):49-59. doi: 10.1164/ajrccm.158.1.9712017.
8
Decline in FEV1 among patients with severe hereditary alpha 1-antitrypsin deficiency type PiZ.PiZ型严重遗传性α1-抗胰蛋白酶缺乏症患者的第一秒用力呼气容积下降
Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):1922-5. doi: 10.1164/ajrccm.152.6.8520756.
9
Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT).来自西班牙注册研究(REDAAT)的α-1抗胰蛋白酶缺乏症患者肺功能的长期演变
Int J Chron Obstruct Pulmon Dis. 2018 Mar 23;13:1001-1007. doi: 10.2147/COPD.S155226. eCollection 2018.
10
Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV in individuals with PiZZ alpha-1-antitrypsin deficiency.对于PiZZ型α-1抗胰蛋白酶缺乏症患者,病情加重和戒烟时长与每年的第一秒用力呼气容积(FEV)损失相关。
Respir Med. 2017 Aug;129:8-15. doi: 10.1016/j.rmed.2017.05.011. Epub 2017 May 24.

引用本文的文献

1
Recommendations for the diagnosis and treatment of alpha-1 antitrypsin deficiency.α-1抗胰蛋白酶缺乏症的诊断和治疗建议。
J Bras Pneumol. 2024 Dec 6;50(5):e20240235. doi: 10.36416/1806-3756/e20240235. eCollection 2024.
2
Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement.α-1抗胰蛋白酶缺乏症作为慢性呼吸系统疾病及与肺气肿不同病症的一种常见可治疗机制?对欧洲呼吸学会新声明的评论
Multidiscip Respir Med. 2018 Oct 8;13:39. doi: 10.1186/s40248-018-0153-4. eCollection 2018.
3
Advances in managing COPD related to α -antitrypsin deficiency: An under-recognized genetic disorder.
α-抗胰蛋白酶缺乏症相关 COPD 的治疗进展:一种被低估的遗传性疾病。
Allergy. 2018 Nov;73(11):2110-2121. doi: 10.1111/all.13558. Epub 2018 Jul 26.
4
Systematic review of the evidence relating FEV1 decline to giving up smoking.系统评价与用力呼气量(FEV1)下降相关的戒烟证据。
BMC Med. 2010 Dec 14;8:84. doi: 10.1186/1741-7015-8-84.
5
Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank.在 Alpha-1 基金会 DNA 和组织库中登记的缺乏个体中进行的 Alpha-1-抗胰蛋白酶增补疗法。
Int J Chron Obstruct Pulmon Dis. 2009;4:443-52. doi: 10.2147/copd.s8577. Epub 2009 Dec 29.
6
Alpha-1-antitrypsin deficiency: current concepts.α-1抗胰蛋白酶缺乏症:当前概念
Lung. 2007 Jul-Aug;185(4):191-201. doi: 10.1007/s00408-007-9009-y. Epub 2007 Jun 12.
7
Transmitting genetic risk information in families: attitudes about disclosing the identity of relatives.在家族中传递遗传风险信息:关于披露亲属身份的态度。
Am J Hum Genet. 1999 Sep;65(3):902-9. doi: 10.1086/302531.
8
Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting.α1抗胰蛋白酶缺乏症:世界卫生组织会议纪要
Bull World Health Organ. 1997;75(5):397-415.
9
Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with alpha 1-antitrypsin deficiency (PiZZ).年龄及职业性气道刺激物暴露对α1-抗胰蛋白酶缺乏症(PiZZ型)非吸烟个体肺功能的影响
Thorax. 1997 Mar;52(3):244-8. doi: 10.1136/thx.52.3.244.
10
Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy.α1-抗胰蛋白酶缺乏症、肺气肿与肝脏疾病。遗传基础及治疗策略。
J Clin Invest. 1990 May;85(5):1343-52. doi: 10.1172/JCI114578.